NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Shanghai Wibson Biotechnology WBS

Published 12 Nov 2026. 36-page investigative report on who is behind Shanghai Wibson Biotechnology WBS: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Shanghai Wibson Biotechnology WBS is not a simple good/bad vendor story. Across 72 Finnrick lab tests, WBS records 51 pass and 20 fail, an overall pass rate of 71%. The useful signal is product-specific: Tirzepatide is the most defensible higher-count line, Retatrutide is supported but traceability-sensitive after a retained underfill/no-batch event, and TB-500 plus Cagrilintide are the clearest weak spots.

The bigger buying problem is authentication. The report maps four live WBS-branded sales surfaces, a parked listed .cn domain, and a public sequence in which a WBS representative labels one site fake, says no official sales website exists, then launches a rep-ordering subdomain days later. Public business sources support a Shanghai foreign-trade operation; they do not verify in-house manufacturing, beneficial ownership, or a disclosed QA and batch-release chain.

The verification layer deserves separate attention. Six lab brands repeat the same WBS dataset, three of them copy Finnrick’s leadership, backers, and mission without naming Finnrick, and sampled Janoshik-branded QR codes point to a WBS-domain lookalike rather than Janoshik’s registrable domain. Shared JavaScript and a TFC tracker tie the polished storefront to a wider peptide-site fleet, while parasite-SEO pages and buyer-complaint texts show why channel hygiene matters.

Inside the full report:

  • Appendix A with per-product Finnrick pass/fail rates, product trajectories, and methodology-divergence charts for all 8 products
  • Four-channel authentication map covering WBS domains, rep posts, and fake-site warnings
  • Janoshik QR and key verification analysis for sampled WBS-branded reports
  • Lab/reference network graph covering Medu, VendorInvestigator, PeptideDetective, Journal Compound, and TalkPeptides
  • Corporate-identity review using LookChem, a Chinese alumni page, WHOIS, and registry-search limitations
  • Shared-code and infrastructure analysis linking WBS storefront assets to sister peptide-site templates

Risk assessment

  • Channel-authentication and copycat risk — high: Multiple live WBS-branded domains conflict; Tiffany called shanghaiwibsonbiotechnology.com fraudulent while shanghaiwibsonbio.com/shanghaiwibsonbiotechnology.net remain unreconciled and no official-channel list is published.
  • COA and independent-verification integrity risk — high: Six lab brands display the same WBS dataset and copied Finnrick identities; seven sampled Janoshik QR codes route to a WBS-domain lookalike and the key did not verify publicly.
  • Product-specific quality risk: Cagrilintide, TB-500 and Tesamorelin — high: Finnrick rates Cagrilintide 48.08%, TB-500 37.93%, and Tesamorelin 51.39%, each with fail-heavy or weak records.
  • Retatrutide fill/traceability risk — high: Finnrick rates Retatrutide 79.07%, but a retained lot event found a 20 mg-labeled vial at 9.98 mg with no batch ID.
  • Mixed-line product-quality risk: Ipamorelin and BPC-157 — medium: Finnrick rates Ipamorelin 62.16% with 4 pass / 3 fail and BPC-157 54.22% with 4 pass / 2 fail; exact-lot testing is needed.
  • Tirzepatide endotoxin-documentation risk — medium: Tirzepatide is WBS’s strongest higher-count line at 86.84%, but a retained endotoxin-only result was marked low rather than clean non-detect.
  • Manufacturing and batch-release transparency risk — medium: WBS claims direct manufacture and warehouses, while public records show a Trading Company listing and no verified factory, QA head, sterility control, or batch-release procedure.
  • Legal accountability and UBO transparency risk — medium: No unified social credit code, legal representative, shareholder, parent entity, UBO, or contracting entity was verified in the reviewed public record.